ProPhase Labs (ProPhase Labs) Gross Margin % : -87.34% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. ProPhase Labs's Gross Profit for the three months ended in Dec. 2023 was $-3.06 Mil. ProPhase Labs's Revenue for the three months ended in Dec. 2023 was $3.50 Mil. Therefore, ProPhase Labs's Gross Margin % for the quarter that ended in Dec. 2023 was -87.34%.

The historical rank and industry rank for ProPhase Labs's Gross Margin % or its related term are showing as below:

PRPH' s Gross Margin % Range Over the Past 10 Years
Min: 19.74 Med: 34.73 Max: 64.25
Current: 36.59

During the past 13 years, the highest Gross Margin % of ProPhase Labs was 64.25%. The lowest was 19.74%. And the median was 34.73%.

PRPH's Gross Margin % is ranked worse than
64.81% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595 vs PRPH: 36.59

ProPhase Labs had a gross margin of -87.34% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for ProPhase Labs was 8.60% per year.

ProPhase Labs Gross Margin % Historical Data

The historical data trend for ProPhase Labs's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Gross Margin % Chart

ProPhase Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

26.48

31.73

53.12

57.61

36.59

ProPhase Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															51.70	54.50	48.79	27.82	-87.34

Competitive Comparison of ProPhase Labs's Gross Margin %

For the Diagnostics & Research subindustry, ProPhase Labs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Gross Margin % distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Gross Margin % falls into.

ProPhase Labs Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

ProPhase Labs's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	16.2	/	44.384
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(44.384 - 28.145)	/	44.384
	=	36.59 %

ProPhase Labs's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.1	/	3.499
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(3.499 - 6.555)	/	3.499
	=	-87.34 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

ProPhase Labs (NAS:PRPH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ProPhase Labs had a gross margin of -87.34% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

ProPhase Labs Gross Margin % Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ProPhase Labs (ProPhase Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530

Website

https://www.prophaselabs.com

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Executives

Morse Robert A. Jr.	officer: Controller	711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White	officer: Chief Financial Officer	191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr	director	902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel	10 percent owner	C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus	10 percent owner	188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch	director	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady	officer: Chief Accounting Officer	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr	officer: Chief Operating Officer	PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal	10 percent owner	THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank	director	104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin	director
Mark A. Burnett	10 percent owner	40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley	director, 10 percent owner, officer: Chairman, President, CEO	C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo	10 percent owner	17 WOLCOTT COURT, BOSTON MA 02136